Bruker Corporation (Nasdaq: BRKR) today announces the launch of the new X4 POSEIDON™, a high-performance 3D X-ray microscope (XRM) using micro-Computed Tomography (microCT). This innovative benchtop XRM system offers advanced capabilities comparable to larger, floor-standing systems to make high-resolution 3D X-ray microscopy accessible for demanding XRM applications in industrial applications and scientific research.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250227078535/en/

X4 POSEIDON – a versatile, high-performance benchtop XRM system (Photo: Business Wire)

The X4 POSEIDON features a high-end X-ray source that improves 3D resolution more than an order of magnitude compared to similar instruments. The system offers a large field-of-view high-efficiency detector, which optionally can be combined with a high-resolution scientific CMOS detector for multi-vision analytical flexibility.

The X4 POSEIDON is powered by 3DxSUITE software, with automated protocols, an intuitive and customizable user interface, integrated database and user management, and multi-language support. Designed for low maintenance, the system enhances uptime and reduces cost of ownership. Options are field-upgradable, allowing for cost-effective expansion to meet evolving analytical needs and future innovations.

Diederik Ellerbroek, Bruker AXS Vice President for Materials Science XRM, stated: “The X4 POSEIDON represents a significant advancement in benchtop XRM design and performance. It offers flexibility and performance for fast 3D high-resolution XRM with a large field of view for industrial and materials science research applications in the geosciences, pharmaceutical R&D and QA/QC, composite materials, batteries, renewable energy, and microelectronics.”

Guillaume Tetard, Bruker Biospin Vice President for Optical and mCT Preclinical Imaging, added: “The X4 POSEIDON is a cutting-edge XRM system with unmatched image quality in its category for performance across life-science applications from bone and dental research, to soft tissue imaging, plant and animal biology.”

About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR)

Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI and HPC. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit www.bruker.com.

Investor Contact: Joseph Kostka Director - Investor Relations Bruker Corporation T: +1 978 313-5773 E: Investor.Relations@bruker.com Media Contact: Markus Ziegler Sr. Director and Head of Group Marketing Bruker BioSpin T: +49 172 3733531 E: pr@bruker.com

Bruker (NASDAQ:BRKR)
과거 데이터 주식 차트
부터 2월(2) 2025 으로 3월(3) 2025 Bruker 차트를 더 보려면 여기를 클릭.
Bruker (NASDAQ:BRKR)
과거 데이터 주식 차트
부터 3월(3) 2024 으로 3월(3) 2025 Bruker 차트를 더 보려면 여기를 클릭.